FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204276921> ?p ?o ?g. }

• W3204276921 abstract "Abstract Background Interleukin-6 receptor antagonists (IL-6RAs) and steroids are emerging immunomodulatory therapies for severe and critical coronavirus disease (COVID-19). In this preliminary report, we aim to describe the epidemiology, clinical characteristics, and outcomes of adult critically ill COVID-19 patients, requiring invasive mechanical ventilation (iMV), and receiving IL-6RA and steroids therapy over the last 11 months. Materials and methods International, multicenter, cohort study derived from Viral Infection and Respiratory Illness University Study registry and conducted through Discovery Network, Society of Critical Care Medicine. Data were collected between March 01, 2020, and January 10, 2021. Results Of 860 patients who met eligibility criteria, 589 received steroids, 170 IL-6RAs, and 101 combinations. Patients who received IL-6RAs were younger (median age of 57.5 years vs. 61.1 and 61.8 years in the steroids and combination groups, respectively). The median C-reactive protein level was > 75 mg/L, indicating a hyperinflammatory phenotype. The median daily steroid dose was 7.5 mg dexamethasone or equivalent (interquartile range: 6–14 mg); 80.8% and 19.2% received low-dose and high-dose steroids, respectively. Of the patients who received IL-6RAs, the majority received one dose of tocilizumab and sarilumab (dose range of 600–800 mg for tocilizumab and 200–400 mg for sarilumab). Regarding the timing of administration, we observed that steroid and IL-6RA administration on day 0 of ICU admission was only 55.6% and 39.5%, respectively. By day 28, when compared with steroid use alone, IL-6RA use was associated with an adjusted incidence rate ratio (aIRR) of 1.12 (95% confidence interval [CI] 0.88, 1.4) for ventilator-free days, while combination therapy was associated with an aIRR of 0.83 (95% CI 0.6, 1.14). IL-6RA use was associated with an adjusted odds ratio (aOR) of 0.68 (95% CI 0.44, 1.07) for the 28-day mortality rate, while combination therapy was associated with an aOR of 1.07 (95% CI 0.67, 1.70). Liver dysfunction was higher in IL-6RA group ( p = 0.04), while the bacteremia rate did not differ among groups. Conclusions Discordance was observed between the registry utilization patterns (i.e., timing of steroids and IL-6RA administration) and new evidence from the recent randomized controlled trials and guideline recommendations. These data will help us to identify areas of improvement in prescribing patterns and enhance our understanding of IL-6RA safety with different steroid regimens. Further studies are needed to evaluate the drivers of hospital-level variation and their impact on clinical outcomes. Trial registration ClinicalTrials.gov: NCT04486521. Registered on July 2020" @default.
• W3204276921 created "2021-10-11" @default.
• W3204276921 creator A5002023162 @default.
• W3204276921 creator A5002885008 @default.
• W3204276921 creator A5002974372 @default.
• W3204276921 creator A5009739204 @default.
• W3204276921 creator A5015841346 @default.
• W3204276921 creator A5016528233 @default.
• W3204276921 creator A5021042489 @default.
• W3204276921 creator A5027402781 @default.
• W3204276921 creator A5027783773 @default.
• W3204276921 creator A5032921567 @default.
• W3204276921 creator A5034055418 @default.
• W3204276921 creator A5034512823 @default.
• W3204276921 creator A5036186737 @default.
• W3204276921 creator A5036529101 @default.
• W3204276921 creator A5037534844 @default.
• W3204276921 creator A5041260566 @default.
• W3204276921 creator A5044161176 @default.
• W3204276921 creator A5060547086 @default.
• W3204276921 creator A5060634958 @default.
• W3204276921 creator A5065987567 @default.
• W3204276921 creator A5072479776 @default.
• W3204276921 creator A5072824454 @default.
• W3204276921 creator A5078316028 @default.
• W3204276921 creator A5083937518 @default.
• W3204276921 creator A5087450706 @default.
• W3204276921 date "2021-10-02" @default.
• W3204276921 modified "2023-09-29" @default.
• W3204276921 title "Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry" @default.
• W3204276921 cites W2009187570 @default.
• W3204276921 cites W2144807892 @default.
• W3204276921 cites W2531269403 @default.
• W3204276921 cites W2769689735 @default.
• W3204276921 cites W2943492071 @default.
• W3204276921 cites W3004626187 @default.
• W3204276921 cites W3011969852 @default.
• W3204276921 cites W3014050022 @default.
• W3204276921 cites W3016661132 @default.
• W3204276921 cites W3022610500 @default.
• W3204276921 cites W3081745349 @default.
• W3204276921 cites W3082108964 @default.
• W3204276921 cites W3084639106 @default.
• W3204276921 cites W3093849061 @default.
• W3204276921 cites W3096119943 @default.
• W3204276921 cites W3107687442 @default.
• W3204276921 cites W3111550855 @default.
• W3204276921 cites W3118685355 @default.
• W3204276921 cites W3129717864 @default.
• W3204276921 cites W3130126061 @default.
• W3204276921 cites W3138470715 @default.
• W3204276921 cites W3139095225 @default.
• W3204276921 cites W3154855659 @default.
• W3204276921 cites W3157916142 @default.
• W3204276921 cites W3165050231 @default.
• W3204276921 cites W3175835730 @default.
• W3204276921 cites W3176830244 @default.
• W3204276921 cites W3181530483 @default.
• W3204276921 cites W3184991811 @default.
• W3204276921 cites W4206449744 @default.
• W3204276921 cites W4210642183 @default.
• W3204276921 cites W4294116629 @default.
• W3204276921 doi "https://doi.org/10.1186/s40001-021-00591-x" @default.
• W3204276921 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8487342" @default.
• W3204276921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34600589" @default.
• W3204276921 hasPublicationYear "2021" @default.
• W3204276921 type Work @default.
• W3204276921 sameAs 3204276921 @default.
• W3204276921 citedByCount "15" @default.
• W3204276921 countsByYear W32042769212021 @default.
• W3204276921 countsByYear W32042769212022 @default.
• W3204276921 countsByYear W32042769212023 @default.
• W3204276921 crossrefType "journal-article" @default.
• W3204276921 hasAuthorship W3204276921A5002023162 @default.
• W3204276921 hasAuthorship W3204276921A5002885008 @default.
• W3204276921 hasAuthorship W3204276921A5002974372 @default.
• W3204276921 hasAuthorship W3204276921A5009739204 @default.
• W3204276921 hasAuthorship W3204276921A5015841346 @default.
• W3204276921 hasAuthorship W3204276921A5016528233 @default.
• W3204276921 hasAuthorship W3204276921A5021042489 @default.
• W3204276921 hasAuthorship W3204276921A5027402781 @default.
• W3204276921 hasAuthorship W3204276921A5027783773 @default.
• W3204276921 hasAuthorship W3204276921A5032921567 @default.
• W3204276921 hasAuthorship W3204276921A5034055418 @default.
• W3204276921 hasAuthorship W3204276921A5034512823 @default.
• W3204276921 hasAuthorship W3204276921A5036186737 @default.
• W3204276921 hasAuthorship W3204276921A5036529101 @default.
• W3204276921 hasAuthorship W3204276921A5037534844 @default.
• W3204276921 hasAuthorship W3204276921A5041260566 @default.
• W3204276921 hasAuthorship W3204276921A5044161176 @default.
• W3204276921 hasAuthorship W3204276921A5060547086 @default.
• W3204276921 hasAuthorship W3204276921A5060634958 @default.
• W3204276921 hasAuthorship W3204276921A5065987567 @default.
• W3204276921 hasAuthorship W3204276921A5072479776 @default.
• W3204276921 hasAuthorship W3204276921A5072824454 @default.
• W3204276921 hasAuthorship W3204276921A5078316028 @default.
• W3204276921 hasAuthorship W3204276921A5083937518 @default.
• W3204276921 hasAuthorship W3204276921A5087450706 @default.
• W3204276921 hasBestOaLocation W32042769211 @default.
• W3204276921 hasConcept C119060515 @default.

• next